Pays: Australie
Langue: anglais
Source: Department of Health (Therapeutic Goods Administration)
flecainide acetate, Quantity: 50 mg
Boucher & Muir Pty Ltd
Flecainide acetate
Tablet, uncoated
Excipient Ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; maize starch; magnesium stearate
Oral
60 tablets
(S4) Prescription Only Medicine
1. Supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. Wolff-Parkinson-White and Lown-Ganong-Levine syndromes. b) due to dual AV nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.,Although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. Life threatening ventricular arrhythmias not controlled by other drugs.,Flecainide BNM tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,Prescribers should also consult the "Precautions" section of this Product Information.
Visual Identification: White circular biconvex tablets embossed C on one face and the identifying letters FI on the reverse.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-11-20